Preclinical Assessment of Dactinomycin in <i>KMT2A</i>-Rearranged Infant Acute Lymphoblastic Leukemia.

ABSTRACT: Background/Objectives: Infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have high rates of relapse and poor survival compared with children. Few new therapies have been identified over the past twenty years. The aim of this study was to identify existing anti-cancer agents that have the potential to be repurposed for the treatment of infant ALL. Methods: Eight extensively characterized infant ALL cell lines were treated with 62 anti-neoplastic drugs in vitro to identify agents that exhibit significant cytotoxicity. From this screen, we selected the most effective and clinically translatable agent for further in vitro and in vivo assessment to determine the potential for use in the clinical setting. Results: Our anti-cancer drug screen reve

SUBMITTER: Chiu SK 

PROVIDER: S-EPMC11816686 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature